Liminatus Pharma (LIMN) Competitors $9.02 +0.21 (+2.38%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock LIMN vs. RCUS, ORIC, AVXL, ZYME, LENZ, AVDL, COGT, OCS, CMRX, and CDMOShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Arcus Biosciences (RCUS), Oric Pharmaceuticals (ORIC), Anavex Life Sciences (AVXL), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Oculis (OCS), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Arcus Biosciences Oric Pharmaceuticals Anavex Life Sciences Zymeworks LENZ Therapeutics Avadel Pharmaceuticals Cogent Biosciences Oculis Chimerix Avid Bioservices Arcus Biosciences (NYSE:RCUS) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Is RCUS or LIMN more profitable? Liminatus Pharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Liminatus Pharma's return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-258.94% -70.58% -32.97% Liminatus Pharma N/A N/A N/A Does the media prefer RCUS or LIMN? In the previous week, Arcus Biosciences had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Arcus Biosciences and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 beat Arcus Biosciences' score of -0.66 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Liminatus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RCUS or LIMN? Arcus Biosciences presently has a consensus target price of $21.29, suggesting a potential upside of 151.46%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, RCUS or LIMN? Liminatus Pharma has lower revenue, but higher earnings than Arcus Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M3.47-$283M-$4.19-2.02Liminatus PharmaN/AN/AN/AN/AN/A Do institutionals and insiders have more ownership in RCUS or LIMN? 92.9% of Arcus Biosciences shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryArcus Biosciences beats Liminatus Pharma on 8 of the 12 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$234.61M$236.28M$2.24B$9.02BDividend YieldN/AN/A2.65%3.99%P/E RatioN/AN/A22.8020.25Price / SalesN/AN/A107.54119.26Price / CashN/AN/AN/A28.59Price / BookN/AN/A165.655.65Net IncomeN/AN/A-$211.97M$249.15M7 Day Performance-19.10%5.05%1.27%2.91%1 Month PerformanceN/A742.27%2.24%4.11%1 Year PerformanceN/A107.60%23.33%20.98% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$9.02+2.4%N/AN/A$234.61MN/A0.00N/AGap UpRCUSArcus Biosciences2.7719 of 5 stars$8.59+2.8%$21.29+147.8%-40.0%$909.55M$141M-2.05500ORICOric Pharmaceuticals4.2422 of 5 stars$10.65+5.0%$19.17+80.0%+40.1%$907.59MN/A-5.7080AVXLAnavex Life Sciences3.5965 of 5 stars$10.57+13.3%$44.00+316.3%+155.8%$902.36MN/A-19.2240Positive NewsZYMEZymeworks2.0771 of 5 stars$12.89+3.9%$21.00+62.9%+44.5%$896.85M$93.38M-8.59460LENZLENZ Therapeutics1.3332 of 5 stars$30.96+3.0%$46.60+50.5%+80.2%$871.52MN/A-17.49110AVDLAvadel Pharmaceuticals2.4005 of 5 stars$8.81flat$18.17+106.2%-39.6%$852.28M$169.12M-32.6370COGTCogent Biosciences2.5922 of 5 stars$7.41+2.6%$14.43+94.7%-9.8%$843.70MN/A-4.0380OCSOculis1.7287 of 5 stars$19.16+1.1%$35.33+84.4%+62.6%$836.53M$780K-7.262CMRXChimerix0.6187 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading Volume Related Companies and Tools Related Companies Arcus Biosciences Competitors Oric Pharmaceuticals Competitors Anavex Life Sciences Competitors Zymeworks Competitors LENZ Therapeutics Competitors Avadel Pharmaceuticals Competitors Cogent Biosciences Competitors Oculis Competitors Chimerix Competitors Avid Bioservices Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIMN Stock Alerts